Naltrexone Alone is NOT Recommended for Weight Loss
Naltrexone monotherapy should not be used for weight loss in otherwise healthy adults, as it has not demonstrated efficacy as a single agent and lacks FDA approval for this indication. 1
Why Naltrexone Alone Doesn't Work
The FDA-approved naltrexone formulation is indicated only for alcohol use disorder and opioid use disorder—not for weight management 1. Clinical trials from the 1980s examining naltrexone monotherapy at doses of 50-200 mg daily showed no significant weight loss compared to placebo:
- One trial showed naltrexone subjects lost only 1.8 kg versus 1.5 kg with placebo (not statistically significant) 2
- Another trial found women lost a modest 1.7 kg while men showed no weight loss at all 3
- Both studies raised hepatotoxicity concerns, with transaminase elevations occurring in multiple subjects 2, 3
The mechanism explains the failure: naltrexone alone produces only weak anorectic effects because β-endorphin has auto-inhibitory activity on hypothalamic anorexigenic neurons. Naltrexone by itself cannot overcome this limitation 4.
The Only Evidence-Based Option: Naltrexone-Bupropion Combination
If considering naltrexone for weight loss, it must be combined with bupropion in the FDA-approved extended-release formulation (naltrexone 8 mg/bupropion 90 mg). The 2022 AGA guidelines conditionally recommend naltrexone-bupropion ER with lifestyle modifications for adults with obesity or overweight with weight-related complications (conditional recommendation, moderate quality evidence) 4.
Why the Combination Works
Bupropion activates anorexigenic neurons but has weak effects alone due to β-endorphin auto-inhibition. Naltrexone blocks this inhibition, creating synergistic weight loss that neither agent achieves individually 4, 5. The combination produces:
- Moderate weight loss: approximately 5-10% total body weight 4
- Dual mechanisms: modulation of hedonic eating plus anorexigenic effects 4
Critical Safety Considerations for the Combination
Absolute contraindications:
- Current or anticipated opioid use (naltrexone blocks opioid efficacy and can precipitate withdrawal) 4
- Seizure disorders (bupropion lowers seizure threshold) 4
- End-stage renal disease 4
Relative contraindications/cautions:
- Moderate-severe hepatic impairment (reduce dose to 1 tablet daily) 4
- Moderate-severe renal impairment (reduce dose to 1 tablet twice daily) 4
Monitoring requirements:
- Blood pressure and heart rate, especially first 12 weeks (modest increases observed in patients with diabetes) 4
- Discontinue if <5% weight loss after 12 weeks at maintenance dose (poor responder) 4
Common adverse effects leading to discontinuation:
- 25% discontinuation rate due to adverse effects versus 10% with placebo 4
- Nausea (4.6-9.6%), vomiting (0.7-2%), headache (0.9-1.8%), dizziness (0.7-1.4%) 4
Dosing Protocol for Naltrexone-Bupropion ER
Start with gradual titration to minimize side effects:
- Week 1: 1 tablet (8 mg/90 mg) each morning
- Week 2: 1 tablet twice daily
- Week 3: 2 tablets morning, 1 tablet afternoon
- Week 4+: Maintenance dose of 2 tablets twice daily
Avoid second dose late in day to prevent insomnia 4.
Clinical Context: Better Alternatives Exist
The 2022 AGA guidelines prioritize semaglutide 2.4 mg over other anti-obesity medications given its superior magnitude of benefit 4. Other options with stronger evidence than naltrexone-bupropion include:
- Tirzepatide: 21% weight loss at 72 weeks (greatest effect) 6
- Semaglutide 2.4 mg: Should be prioritized for most patients 4
- Liraglutide 3.0 mg: Conditional recommendation with moderate evidence 4
Naltrexone-bupropion may be preferentially considered for patients with comorbid depression or those attempting smoking cessation, given bupropion's additional therapeutic effects 4.
Bottom Line
Naltrexone monotherapy has no role in weight management. The only evidence-based use of naltrexone for weight loss is the FDA-approved combination product with bupropion, used alongside lifestyle modifications in patients with obesity or weight-related complications—and only after careful screening for contraindications, particularly opioid use and seizure risk.